Back to Menu
Anal cancer is a malignant tumor occurring in the anal region, primarily arising from epithelial cells of the anal canal. It is relatively rare, accounting for approximately 1%–2% of gastrointestinal malignancies, and is closely associated with HPV infection. Clinical presentations vary; early disease may be asymptomatic, whereas advanced disease can present with bleeding, pain, and defecatory difficulty.
The most common type (>80%), arising from anal squamous epithelium and associated with HPV infection.
Less common, including rectal-type adenocarcinoma and anal gland carcinoma, with distinct biological behavior.
Often arises in the transitional zone of the anal canal, is relatively aggressive, and requires active treatment.
Rare but highly aggressive, with early metastasis and very poor prognosis.
Including small-cell and large-cell carcinomas; rare and highly malignant.
Classified as anal margin cancer and anal canal cancer, which influence treatment strategy and prognosis.
Classified as well-, moderately, or poorly differentiated; poorly differentiated tumors are the most aggressive.
1. HPV infection
The primary risk factor; persistent infection with high-risk HPV-16/18 promotes carcinogenesis.
2. Smoking
Significantly increases risk and is associated with multiple malignancies.
3. Immunosuppression
Risk is increased in organ transplant recipients and individuals with HIV infection due to impaired immunity.
4. Age
Most common in people older than 60 years, with incidence rising with age.
5. Chronic local irritation
Long-standing anal fistulae and chronic inflammation may contribute to malignant transformation.
6. Sexual behavior factors
Multiple sexual partners and a history of anal intercourse increase the risk of HPV acquisition.
7. Genetic and cancer-history–related factors
A history of cervical cancer or vulvar cancer is associated with increased risk.
HPV vaccination in eligible populations prevents infection with oncogenic HPV types and reduces risk.
High-risk individuals should undergo regular anorectal examinations to detect precancerous lesions and early tumors.
Balanced diet, appropriate exercise, and smoking cessation reduce the risk of multiple malignancies.
Condom use reduces HPV transmission, and limiting the number of sexual partners supports health protection.
Awareness of anal cancer symptoms and prompt medical evaluation for abnormal bleeding or a mass help avoid delayed diagnosis.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that anal cancer is associated with HPV infection and that early symptoms are nonspecific and may be misattributed to hemorrhoids, leading to delayed diagnosis. Strengthening prevention is essential through HPV vaccination and regular anorectal examinations. Prompt evaluation is recommended for abnormal bleeding or a mass. Early standardized treatment can improve prognosis while preserving anal function, and MDT-based individualized planning can enhance therapeutic outcomes.
Anal cancer is a malignant tumor occurring in the anal region, primarily arising from epithelial cells of the anal canal. It is relatively rare, accounting for approximately 1%–2% of gastrointestinal malignancies, and is closely associated with HPV infection. Clinical presentations vary; early disease may be asymptomatic, whereas advanced disease can present with bleeding, pain, and defecatory difficulty.
The most common type (>80%), arising from anal squamous epithelium and associated with HPV infection.
Less common, including rectal-type adenocarcinoma and anal gland carcinoma, with distinct biological behavior.
Often arises in the transitional zone of the anal canal, is relatively aggressive, and requires active treatment.
Rare but highly aggressive, with early metastasis and very poor prognosis.
Including small-cell and large-cell carcinomas; rare and highly malignant.
Classified as anal margin cancer and anal canal cancer, which influence treatment strategy and prognosis.
Classified as well-, moderately, or poorly differentiated; poorly differentiated tumors are the most aggressive.
1. HPV infection
The primary risk factor; persistent infection with high-risk HPV-16/18 promotes carcinogenesis.
2. Smoking
Significantly increases risk and is associated with multiple malignancies.
3. Immunosuppression
Risk is increased in organ transplant recipients and individuals with HIV infection due to impaired immunity.
4. Age
Most common in people older than 60 years, with incidence rising with age.
5. Chronic local irritation
Long-standing anal fistulae and chronic inflammation may contribute to malignant transformation.
6. Sexual behavior factors
Multiple sexual partners and a history of anal intercourse increase the risk of HPV acquisition.
7. Genetic and cancer-history–related factors
A history of cervical cancer or vulvar cancer is associated with increased risk.
HPV vaccination in eligible populations prevents infection with oncogenic HPV types and reduces risk.
High-risk individuals should undergo regular anorectal examinations to detect precancerous lesions and early tumors.
Balanced diet, appropriate exercise, and smoking cessation reduce the risk of multiple malignancies.
Condom use reduces HPV transmission, and limiting the number of sexual partners supports health protection.
Awareness of anal cancer symptoms and prompt medical evaluation for abnormal bleeding or a mass help avoid delayed diagnosis.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that anal cancer is associated with HPV infection and that early symptoms are nonspecific and may be misattributed to hemorrhoids, leading to delayed diagnosis. Strengthening prevention is essential through HPV vaccination and regular anorectal examinations. Prompt evaluation is recommended for abnormal bleeding or a mass. Early standardized treatment can improve prognosis while preserving anal function, and MDT-based individualized planning can enhance therapeutic outcomes.